Spinraza remains a big product for Biogen, but has seen its sales go into reverse as competition in SMA treatment has emerged ...

Biogen’s applications for the higher dose regimen of SMA drug Spinraza are now under review in the US and Europe.

The parents of two-year-old Aakriti Singh diagnosed with Spinal Muscular Atrophy – SMA type-1, are worried about her next ...

However, Biogen’s Spinraza faces competition from Novartis’ NVS gene therapy Zolgensma and Roche RHHBY/PTC Therapeutics’ Evrysdi, both of which are approved in SMA indication. Competition from both ...

Spinraza faces increasing competition from the likes of Novartis' (NVS) Zolgensma (a curative option), which often attracts newly diagnosed patients, and Roche's Evrysdi, which attracts existing ...

Spinraza – approved in the US in 2016 and Europe in 2017 ... according to GlobalData’s Pharma Intelligence Center. By contrast, Evrysdi and Zolgensma are expected to generate $2.78bn and $2.13bn in ...

Existing disease-modifying SMA therapies — Spinraza, Evrysdi (risdiplam), and the gene therapy Zolgensma (onasemnogene abeparvovec-xioi) — can provide significant motor and respiratory benefits to ...